Aptevo Therapeutics Inc. - Common Stock (APVO)
1.4050
-0.5850 (-29.40%)
NASDAQ · Last Trade: Apr 5th, 4:03 AM EDT
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Via Chartmill · April 4, 2025
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · April 4, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Via Chartmill · April 4, 2025

Aptevo stock is trading lower after the company announced a 1-for-37 reverse stock split.
Via Benzinga · November 29, 2024
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via Chartmill · April 3, 2025
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Via Chartmill · April 3, 2025
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · April 3, 2025
Via Benzinga · April 3, 2025
The company said that net proceeds from the offering will be used for the continued clinical development of product candidates, as working capital, and for other general corporate purposes.
Via Stocktwits · April 3, 2025
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · April 3, 2025
Via Benzinga · April 3, 2025
Via Benzinga · April 3, 2025
The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · April 2, 2025
Via Benzinga · April 2, 2025
Aptevo Therapeutics reports strong remission rates in AML patients using mipletamig plus ven/aza, with Cohort 2 enrollment nearing completion.
Via Benzinga · March 20, 2025

Via Benzinga · December 12, 2024

Via Benzinga · October 29, 2024

Via Benzinga · October 23, 2024

Via Benzinga · October 23, 2024

Via Benzinga · October 22, 2024

Via Benzinga · October 21, 2024